---
document_datetime: 2023-09-21 19:18:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/veyvondi-epar-all-authorised-presentations_en.pdf
document_name: veyvondi-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7788249
conversion_datetime: 2025-12-20 00:14:21.540588
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU (MA) Number   | (Invented) name   | Strength   | Pharmaceutical Form                           | Route of Administration   | Immediate Packaging                         | Content (concentration)                    | Pack size                               |
|------------------|-------------------|------------|-----------------------------------------------|---------------------------|---------------------------------------------|--------------------------------------------|-----------------------------------------|
| EU/1/18/1298/001 | VEYVONDI          | 650 IU     | Powder and solvent for solution for injection | Intravenous use           | powder: vial (glass); solvent: vial (glass) | powder: 650 IU; solvent:5 ml (130 IU/ml)   | 1 vial + 1 vial + reconstitution device |
| EU/1/18/1298/002 | VEYVONDI          | 1300 IU    | Powder and solvent for solution for injection | Intravenous use           | powder: vial (glass); solvent: vial (glass) | powder: 1300 IU; solvent:10 ml (130 IU/ml) | 1 vial + 1 vial + reconstitution device |